Considering hepatotoxicity to be a common adverse effect in AAV clinical trials ( 45 ), reduced infection of liver cells—to which AAV-DJ has strong tropism—is highly significant when engineering nanobody–AAV for in vivo applications.
← all excerpts
Unlocking precision gene therapy: harnessing AAV tropism with nanobody swapping at capsid hotspots.
1
—
—